Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study
about
A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistencyA novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataCompliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISACalcium citrate and vitamin D in the treatment of osteoporosis.Implementing adherence to osteoporosis treatments.Adoption of once-monthly oral bisphosphonates and the impact on adherence.Efficacy of ibandronate: a long term confirmation.Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.Adherence to osteoporosis treatments: room for improvementLong-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial.Zoledronic acid infusion for prevention and treatment of osteoporosisOral bisphosphonate compliance and persistence: a matter of choice?Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.Adherence and occurrence of fractures after switching to once-monthly oral bisphophonatesSafety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trialsInterventions to improve adherence and persistence with osteoporosis medications: a systematic literature review.Medical treatment of osteoporotic vertebral fractures.Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional studyClinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.Bisphosphonates for the treatment of osteoporosis: insights for clinicians.Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.Which Bisphosphonate? It's the Compliance!: Decision Analysis.Patient preference in the management of postmenopausal osteoporosis with bisphosphonates.Valid treatment options for osteoporosis and osteopenia in HIV-infected persons.Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations.Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study.Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.Adherence to monthly and weekly oral bisphosphonates in women with osteoporosisPoor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.Denosumab for the management of postmenopausal osteoporosis.Overcoming problems with adherence to osteoporosis medication.Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis.Zoledronic acid for prevention and treatment of osteoporosis.Partial adherence: a new perspective on health economic assessment in osteoporosis.Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.
P2860
Q30430605-FCF807B4-FFD5-430F-B889-6E2E23AE8BE4Q30577427-04EBC096-BB6F-4C92-8792-CEB68573B582Q30988951-292B9B7B-7CAF-4402-A50D-7359A9C80212Q33449783-33A027CA-7DD6-4BF6-AA3B-02BE7A0F1746Q33610273-EA55F6EB-EFB3-4210-8B87-51986C4831FAQ33701964-2C1C961A-72AA-4D09-A0C9-FB4A98B4D025Q33965657-C569BDC0-4BA0-4358-B6D4-09CA8DF1BC83Q33973902-EBCE731D-031E-4157-A365-70E7328C9B59Q34033742-43CE7564-8E41-4840-8B43-722062C1965EQ34041189-61B7728C-D900-4F32-BAD3-A1ECB4D33A0BQ34070998-DF78786E-0F91-43CF-B9FA-2767829D72DEQ34345697-B483BEC2-3C6A-411F-9806-D64F3C716D40Q34472700-887B979E-A198-4061-BAC2-7AD5333B55ACQ34699332-8FDB4171-4578-4ACD-A847-EDA97AC9FB74Q34774658-C083597F-269D-4E77-B56F-B395499D5813Q34821660-D69A4836-3D76-4860-ACF4-6C877C00C7F8Q35026446-7EAF996C-0273-480F-9A30-6D3C708A4FCAQ35331699-2295C7C0-48F5-4531-82A5-ACD79FB5504CQ35669367-212ABB1C-67B9-486F-903A-942409D626B5Q36059589-1E2CBF63-3CA3-4433-90BF-0026E2F69EC5Q36073613-1414096E-349D-452C-9A15-2613A8AFAFC9Q36162247-25DCDD2B-7401-49AB-93C6-01FAE240E79AQ36343783-2A916204-FE55-4027-A968-BAB0226E78BBQ36443681-288EFDC6-6C61-4DF8-B31B-E35785B8F25FQ36897441-8042E4F0-9649-4957-AB0E-53E7FD1519D8Q36989633-8C26EDE0-6D09-48C1-9E65-604DDE1AF4FDQ37018957-5E7D22C2-13F5-4E5A-B69C-9EF93CBFFC09Q37138859-E9DA3F7C-9C11-4623-B76C-6D38E7CBD697Q37192994-883E5356-BD59-4C2A-9439-D8A26F9302D5Q37376275-FC17B4AF-E80A-4781-B006-7E1305E5C513Q37402282-F03AA003-6601-45A0-83BB-A638657A8364Q37457324-66095BF4-2459-4582-92AF-BA699D19F3FCQ37565638-7AEC718C-8963-417D-9B75-143FD6F8E9EBQ37768696-9B44CB52-CF86-4724-BA66-00E50D4340C4Q37810423-A695B89E-F9C2-4AA3-BD3F-B15F5CAAB62CQ37820680-F4CCCEA2-551C-4FC4-947D-EEE20E7F8DBDQ37827874-B89E0DCB-80AA-41A7-97F0-77F183EF6338Q37850819-8705FF97-1CF5-4054-8DA6-A5DE21CCF03CQ37880657-5B34BA0B-C9BC-42DE-81F6-04CA9DB96B47Q39038512-034ECA54-F40F-48B2-847C-789828EE0372
P2860
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Treatment persistence with onc ...... results from the PERSIST study
@ast
Treatment persistence with onc ...... results from the PERSIST study
@en
type
label
Treatment persistence with onc ...... results from the PERSIST study
@ast
Treatment persistence with onc ...... results from the PERSIST study
@en
prefLabel
Treatment persistence with onc ...... results from the PERSIST study
@ast
Treatment persistence with onc ...... results from the PERSIST study
@en
P2093
P2860
P1476
Treatment persistence with onc ...... results from the PERSIST study
@en
P2093
PERSIST Investigators
P2860
P304
P356
10.1111/J.1742-1241.2006.01059.X
P577
2006-06-19T00:00:00Z